Immune Dysfunction in Allergic Asthma

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Mark Schuyler, University of New Mexico
ClinicalTrials.gov Identifier:
NCT00189228
First received: September 10, 2005
Last updated: January 18, 2013
Last verified: January 2013
  Purpose

We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.


Condition Intervention
Asthma
Drug: Xolair

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma

Resource links provided by NLM:


Further study details as provided by University of New Mexico:

Primary Outcome Measures:
  • anti-KLH antibody [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Asthma and control patients are immunized with KLH


Enrollment: 18
Study Start Date: September 2005
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: xolair
This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization.
Drug: Xolair
Patients are administered Xolair
Other Name: Xolair

Detailed Description:

Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Mild asthma, adults -

Exclusion Criteria:

children. on inhaled or systemic steroids

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00189228

Locations
United States, New Mexico
UNM HSC
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Study Director: Mark Schuyler, MD UNM HSC
  More Information

No publications provided

Responsible Party: Mark Schuyler, Professor of Medicine, University of New Mexico
ClinicalTrials.gov Identifier: NCT00189228     History of Changes
Obsolete Identifiers: NCT00201097
Other Study ID Numbers: UNMSCOR, R01HL044253
Study First Received: September 10, 2005
Last Updated: January 18, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Omalizumab
Anti-Allergic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on September 22, 2014